Vertex Pharmaceuticals (VRTX) said Thursday it has signed a reimbursement deal with the Italian Medicines Agency for eligible patients to access Casgevy, a gene-edited therapy to treat transfusion-dependent beta thalassemia and severe sickle cell disease.

Financial terms were not disclosed.